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Abstract
Background: Sarcomeric gene mutations cause hypertrophic cardiomyopathy (HCM). In gene mutation carriers
without left ventricular (LV) hypertrophy (G + LVH-), subclinical imaging biomarkers are recognized as predictors of
overt HCM, consisting of anterior mitral valve leaflet elongation, myocardial crypts, hyperdynamic LV ejection fraction,
and abnormal apical trabeculation. Reverse curvature of the interventricular septum (into the LV) is characteristic of
overt HCM. We aimed to assess LV septal convexity in subclinical HCM.
Methods: Cardiovascular magnetic resonance was performed on 36 G + LVH- individuals (31 ± 14 years, 33 % males)
with a pathogenic sarcomere mutation, and 36 sex and age-matched healthy controls (33 ± 12 years, 33 % males).
Septal convexity (SCx) was measured in the apical four chamber view perpendicular to a reference line connecting the
mid-septal wall at tricuspid valve insertion level and the apical right ventricular insertion point.
Results: Septal convexity was increased in G + LVH- compared to controls (maximal distance of endocardium to
reference line: 5.0 ± 2.5 mm vs. 1.6 ± 2.4 mm, p ≤ 0.0001). Expected findings occurred in G + LVH- individuals:
longer anterior mitral valve leaflet (23.5 ± 3.0 mm vs. 19.9 ± 3.1 mm, p ≤ 0.0001), higher relative wall thickness
(0.31 ± 0.05 vs. 0.29 ± 0.04, p ≤ 0.05), higher LV ejection fraction (70.8 ± 4.3 % vs. 68.3 ± 4.4 %, p ≤ 0.05), and smaller
LV end-systolic volume index (21.4 ± 4.4 ml/m2 vs. 23.7 ± 5.8 ml/m2, p ≤ 0.05). Other morphologic measurements
(LV angles, sphericity index, and eccentricity index) were not different between G + LVH- and controls.
Conclusions: Septal convexity is an additional previously undescribed feature of subclinical HCM.
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Background
Hypertrophic cardiomyopathy (HCM) is the most common
inherited monogenetic cardiac disease [1]. Approximately
60 % of cases are known to be caused by the presence of
inherited sarcomeric protein mutations. However these
mutations may have incomplete expression with a variable
phenotype and age-related expression. The first degree rela-
tives of individuals with HCM therefore have approximately
a 50 % pretest probability of genetic carriage. Genotyping
may help identify this but is sometimes inconclusive or
non-contributory. There is however, a subtle subclinical
phase of HCM. Gene mutation carriers without left ven-
tricular (LV) hypertrophy (G + LVH-) have been found by
cardiovascular magnetic resonance (CMR) to have: elon-
gated anterior mitral valve leaflets (AMVL) [2], myocardial
crypts [3–5], hyperdynamic LV ejection fraction, and ab-
normal apical LV trabeculation (measured using fractal
analysis) [6, 7]. Additional features that may be present are
markers of fibrosis [8, 9] and echocardiographic markers of
diastolic dysfunction [10]. We suspect that this list is in-
complete: specifically, that CMR research has really not
fully exploited the insights from echocardiography and that
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some features are being missed particularly in term of LV
global and regional morphology.
The collaboration between CMR specialists and echo-
cardiologists permits the sharing of skills and ideas.
For example, LV morphology has been extensively and
classically characterized by echocardiography using specific
parameters and indexes (sphericity, eccentricity, relative
wall thickness) [11], most of which could also be readily
applied to CMR [12].
Patients with overt HCM (with clinical hypertrophy)
display abnormal LV septal curvature: in the normal heart
the interventricular septum is either in a neutral position or
has a characteristic convexity into the right ventricle (RV);
whilst overt HCM is associated with reverse septal curva-
ture leading to a typical “banana-like” LV cavity [13–18].
The presence of reverse septal curvature “convexity” in
overt HCM is associated with a higher prevalence of
identified sarcomere gene mutation [18] and may have
an impact on regional strain in these patients [19]. Fur-
thermore, various angles (angle between the LV long
axis and mitral valve, angle between papillary muscles
insertion points, and angle between LV long axis and
aortic root) are different in overt HCM compared to
those in a normal heart [20]. We therefore hypothesized
that abnormal LV septal curvature, as well as several
other morphological abnormalities (angles, indexes), may
be present before hypertrophy in G + LVH- individuals
and be a component of subclinical HCM.
Methods
Study population
A collaborative group at the Heart Hospital (University
College London, United Kingdom) have previously cre-
ated and published a case–control cohort [7] composed
of G + LVH- HCM participants matched to healthy vol-
unteers on the basis of age (±8 years), sex, body surface
area (BSA ±10 %), and ethnicity. Inclusion criteria for
the G + LVH− group included: (1) maximal LV wall
thickness <13 mm by CMR and mass within the normal
range relative to BSA, age, and sex; (2) sinus rhythm,
no LVH, and no pathological Q waves/T-wave inversion
on 12-lead electrocardiography; and (3) no causes of
secondary LVH (valve disease, hypertension). Healthy
volunteers had no history of cardiovascular disease or
hypertension, a normal physical examination, no family
history of inheritable cardiomyopathy or sudden cardiac
death, and no personal history of cardiac symptoms or
cardiovascular disease (including hypertension) and with a
normal physical examination and ECG. Exclusion criteria
for all participants were the presence of conventional con-
traindications for CMR, claustrophobia, and arrhythmias
(e.g., atrial fibrillation, frequent atrial or ventricular ec-
topics). An ethics committee of the UK National Research
Ethics Service approved the generic analysis of anonymized
clinical scans. The genotyping project was approved by the
UCL/UCLH Joint Research Ethics Committee. All partici-
pants gave written informed consent conforming to the
Declaration of Helsinki (fifth revision, 2000). Study data
were collected and managed using REDCap electronic data
capture tool (Research Electronic Data Capture, REDCap
Software - Version 5.9.6, http://www.project-redcap.org/).
Electrocardiography
Standard 12-lead electrocardiography was performed in
the supine position during quiet respiration. LVH was
evaluated with the Romhilt-Estes [21] and electrocardio-
graphic European criteria [22, 23]. Electrocardiographic
images were analyzed by an experienced observer blinded
to clinical and CMR data.
Genetic screening
Genomic analysis of this cohort has been previously de-
scribed in detail [7, 24, 25]. G+ individuals were defined as
the ones carrying a known disease causing mutation in one
of the following sarcomere genes: myosin-binding protein
C (MYBPC3), β-myosin heavy chain (MYH7), troponin
T (TNNT2), troponin I (TNNI3), myosin regulatory
light chain (MYL2), myosin essential light chain (MYL3),
tropomyosin (TPM1), and cardiac α-actin (ACTC1).
Cardiovascular magnetic resonance image acquisition
Standard clinical scans (localizers, 3 long-axis views, black
and white blood images, full LV short-axis stack) were per-
formed using a 1.5-T magnet (Avanto, Siemens Medical
Solutions®, Erlangen, Germany). CMR short-axis volumet-
ric studies [26] were acquired from retrospectively gated,
breath-held, balanced, steady-state free-precession cines
(slice thickness, 7 mm; interslice gap, 3 mm; flip angle,
60°–80°; repetition time, 3.0 ms; echo time, 1.33 ms; field
of view read typically, 380 mm; phase resolution, 75 %;
typical acquired voxel size, 1.5 × 1.7 mm; 12 lines per
segment). Late gadolinium enhancement images acquired
through an inversion recovery turbo fast low-angle shot
sequence were obtained 7 to 15 min after injection of
0.1 mmol/kg gadolinium-diethylenetriamine penta-acetic
acid.
Cardiovascular magnetic resonance analysis
The morphology, systolic function and the structure of
the LV were evaluated by cardiologists experienced in
CMR (PR, MM). All CMR measurements were blinded
to gene status. The presence of fibrosis and the structure
of the LV were evaluated by other cardiologists experi-
enced in CMR (JCM, GC, DMS).
Standard CMR measurements
LV volumes, LV ejection fraction (EF), LV outflow tract
diameter, and LV mass were determined according to
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standardized CMR methods [27] (papillary muscles were
included in the LV mass). LV wall thickness was measured
at the septum and posterior wall on end-diastolic short-
axis cine frames. The ratio of maximal septal diastolic wall
thickness to posterior wall thickness was calculated, as
well as relative wall thickness according to echocardio-
graphic guidelines [11].
Measurement of septal convexity
The convexity of the interventricular septum into the LV
was measured from the apical 4-chamber view as the
maximal distance between LV septal endocardial border
at mid LV level and a line connecting mid-wall points
at the level of tricuspid valve insertion and at the level
of apical right ventricular (RV) insertion on the LV
(Fig. 1). Septal convexity (SCx) was expressed positively.
In case of concavity (corresponding to convexity into
the RV – the normal arrangement), the measure was
expressed negatively. In addition, on the 3 consecutive
short axis views at papillary muscle level, an evaluation of
the septal convexity was performed measuring the maximal
distance between LV endocardial border and a reference
line joining the epicardium of the LV-RV insertion points
(B to A) (Fig. 2).
Fig. 1 Measurement of septal convexity (SCx) in apical 4 chamber view: performed as the maximal distance (A to B) between the LV endocardial
border (B) and the intersection point (A), perpendicularly to a reference line joining at mid-wall the level of tricuspid valve insertion (C) and the
apical right ventricular insertion point into the LV (D) in a 49-year old G + LVH- male (a), and in a matched healthy control (b)
Fig. 2 Measurement of septal convexity in short axis: views at papillary muscle level as the distance (A to B) between septal LV endocardial border (B)
and the perpendicular intersection point (A) of a reference line connecting the epicardial RV insertion points into LV (anteriorly: C, and inferiorly: D)
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Measurement of other previously-described markers of
HCM
LV mitral angle, mitral papillary muscles angle, and
LV-aortic root angle were analyzed on the open source
software OsiriX® (http://www.osirix-viewer.com) as previ-
ously described [20]. The angle between LV outflow tract
and basal septum was also analyzed. Left ventricular
end-diastolic sphericity index was measured (as previ-
ously described), as the ratio of LV end-diastolic diam-
eter measured in short axis view at papillary muscle
level (septal to lateral wall distance) divided by the LV
end-diastolic long axis diameter measured in the apical 4
chamber view [12]. LV end-diastolic and end-systolic
eccentricity indexes were calculated in the short-axis at
the level of papillary muscles as the ratio of septal to
lateral wall distance divided by inferior to anterior wall
distance [11].
LV end-systolic left atrial areas were measured by
planimetry on 4-chamber view. Anterior mitral valve
leaflet (AMVL) length was measured using the method
previously described by Maron et al. [2] Additionally,
the mitral valve annulus was measured in mid diastole
in the apical 3 chamber view. The 3 long-axis views and a
modified 2-chamber view (transecting RV insertion
points) were evaluated for the presence of myocardial
crypts defined as focal myocardial defects with a depth
of ≥50 % of the adjacent myocardium [5].
Statistical analysis
Descriptive data were analyzed for normality using the
Shapiro-Wilks test and were expressed as mean ± stand-
ard deviation except where otherwise stated. Categorical
variables were compared using χ2 tests. Non-categorical
data were directly compared using paired t test. An opti-
mal threshold value for SCx within this case–control
population was calculated as the Youden Index derived
from the area under the receiver operating characteristics
curve. Mean variability within and between readers was
evaluated using the mean of differences between two
measurements. Paired measurements for repeatability
of SCx were evaluated using the Bland–Altman method
[28]. A 2-sided p value <0.05 was considered signifi-
cant. Statistical analysis was performed using SPSS for
Windows version 20.0 (Chicago, IL).
Results
Patient characteristics
The study population consisted of 36 G + LVH- individuals
(aged 15–62 years) with complete DICOM short and long
axis images from within the original Heart Hospital cohort.
G + LVH- cases deriving from 30 unrelated families, were
compared to 36 matched healthy volunteers (aged 14–59
years) (Table 1). Children and adolescents (aged <18 years)
comprised 20 % of the G + LVH- cohort. Thirty five unique
mutations in a total of 6 sarcomere genes were represented
across the G + LVH- population: MYBPC3, n = 16; MYH7,
n = 6; MYL2, n = 0; TNNT2, n = 4; TNNI3, n = 7; and
ACTC1, n = 2, with mutations in MYBPC3 (47 %) and
Table 1 Demographic and imaging characteristics of G + LVH-
compared to controls
Characteristics G + LVH- Controls Univariate
(n = 36) (n = 36) p value
Male gender, n (%) 12 (33) 12 (33) >0.99
Age, years 31.3 ± 13.8 33.4 ± 12.2 0.053
Ethnicity* A = 35 A = 35 >0.99
D = 1 D = 1 0.60
Body surface area, m2 1.8 ± 0.2 1.8 ± 0.2 0.60
Septal wall thickness, mm 8.9 ± 1.9 8.4 ± 1.2 0.13
Posterior wall thickness, mm 6.4 ± 1.4 6.4 ± 1.4 0.86
Septal/posterior wall thickness ratio 1.41 ± 0.31 1.36 ± 0.31 0.59
LV mass index, g/m2 57.8 ± 11.7 59.1 ± 12.8 0.65
Relative wall thickness 0.31 ± 0.05 0.29 ± 0.04 0.039
LV end-diastolic volume index, mL/m2 73.2 ± 9.8 74.4 ± 11.2 0.60
LV end-systolic volume index, mL/m2 21.4 ± 4.4 23.7 ± 5.8 0.048
LV ejection fraction, % 70.8 ± 4.3 68.3 ± 4.4 0.022
LV long axis end-diastolic diameter, mm 92.2 ± 7.6 92.7 ± 6.3 0.63
LV transversal end-diastolic diameter,
mm
47.3 ± 3.7 48.8 ± 3.9 0.10
LV end-diastolic sphericity index 0.52 ± 0.05 0.54 ± 0.05 0.21
LV end-diastolic eccentricity index 0.90 ± 0.06 0.90 ± 0.06 0.62
LV end-systolic eccentricity index 0.88 ± 0.06 0.89 ± 0.07 0.55
LV-mitral angle,° 83.2 ± 5.7 83.6 ± 3.5 0.54















Septal convexity (A4C) into LV (SCx), mm 5.0 ± 2.5 1.6 ± 2.4 <0.0001
Septal convexity Sax1 at PM level 10.7 ± 3.7 12.0 ± 3.1 0.11
Septal convexity Sax2 at PM level 10.1 ± 3.4 11.5 ± 3.5 0.098
Septal convexity Sax3 at PM level 8.9 ± 3.3 9.8 ± 3.9 0.37
Myocardial crypts (≥1), n (%) 11 (30 %) 3 (8 %) 0.017
LVOT end-diastolic diameter, mm 21.8 ± 2.4 21.6 ± 1.9 0.73
LVOT end-systolic diameter, mm 18.2 ± 2.2 18.8 ± 2.0 0.21
Anterior mitral valve leaflet length, mm 23.5 ± 3.0 19.9 ± 3.1 <0.0001
Mitral valve annulus diameter, mm 29.4 ± 3.9 30.7 ± 3.2 0.18
Left atrial area index, cm2/m2 10.9 ± 1.5 10.7 ± 1.4 0.73
*Ethnic headings are defined in accordance with UK Office for National Statistics
guidance on national standards: A indicates white; B, mixed; C, Asian or Asian Black
D, black or Black British; E, Chinese or other ethnic group (including Arab)
LV Left ventricular, A4C Apical 4 chamber view, PM Papillary muscles, SAX
Short axis views at 10 mm interval at PMs level (1,2,3), LVOT Left ventricular
outflow tract
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MYH7 (17 %) being most prevalent. There was one
multiple-mutation carrier (MYBPC3 and TNNI3).
Morphological findings: septal convexity and other
measurements
Baseline CMR parameters (Table 1) for G + LVH- patients
were similar to the control group, except for LVEF, LV
end-systolic volume index, and AMVL length. There were
two other differences: septal convexity into LV (5.0 ± 2.5
vs. 1.6 ± 2.4 mm, p < 0.0001, see Figs. 3a and b) and
relative wall thickness (0.31 ± 0.05 vs. 0.29 ± 0.04 mm;
p = 0.039) were greater in G + LVH- subjects than con-
trols (Table 1). Convexity of the septum evaluated in
short axis was not significantly different compared to
healthy controls (Table 1). There were no significant
differences between G + LVH- and control group con-
cerning LV outflow tract diameter, the different angles,
LV sphericity, and eccentricity indexes. Figure 1 depicts an
example of convexity of the septum into the LV in a G +
LVH- subject compared to the matched healthy control.
Figure 4 displays the receiver operating characteristics
curve analysis of LV septal convexity into LV to predict mu-
tation carriers. AUC was 0.87 (95 % CI = 0.79−0.95). The
cut-off point providing both the best balance between
sensitivity (77 %) and specificity (89 %) was of >3.55 mm.
Figure 5 depicts the good intra- and inter-observer repro-
ducibility for SCx measurement according to Bland-
Altman analysis.
As expected, myocardial crypts were more common in
G + LVH- patients (11/36; 30 vs healthy volunteers 3/36;
8 %; p = 0.017). G + LVH- patients with at least one crypt
had mean SCx values of 6.0 ± 3.1 mm while patients
without crypt (n = 25) had a mean value of 4.6 ± 2.2 mm
(p = 0.12).
G + LVH- individuals with isolated MYBPC3 mutation
(n = 16) had a mean SCx of 5.3 ± 2.7 mm while individuals
with other mutations a mean SCx of 4.7 ± 2.3 mm (p =
Fig. 3 a Mean SCx in G + LVH- compared to healthy controls. b SCx for each G + LVH- and corresponding matched healthy control
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0.45). Individuals with thick filament mutations (MYBPC3
and MYH7) tended to have greater SCx than individuals
with thin filament mutations (TNNT2, TNNI3, and ACTC)
(5.4 ± 2.5 mm vs. 4.2 ± 2.4, p = 0.16).
Late gadolinium enhancement was absent in all G +
LVH− patients and healthy volunteers.
Discussion
These data show that in subclinical HCM, gene mutation
carriers with normal ECGs and no LVH (G + LVH-)
exhibit abnormal convexity of the interventricular septum
into the LV. Four other features described here (crypts,
AMVL length, and markers of elevated LV systolic
function and apical abnormal trabeculae) have been
previously identified using CMR [2, 7], as well as myo-
cardial fibrosis [8, 9] and diastolic dysfunction on
echocardiography [10]. These findings represent the
known subclinical HCM phenotype.
Patients with HCM are at risk of developing complica-
tions such as heart failure, atrial fibrillation, stroke, and
sudden cardiac death. Consequently, the detection of a
subclinical HCM phenotype [29–32] in relatives of pro-
bands may facilitate closer clinical surveillance [33], and
may provide markers for future therapeutic trials, par-
ticularly where genetic analysis is non-contributory [34].
This paper advances the field by the identification of one
new feature – abnormal septal convexity. This was found
by increasing the collaboration between CMR experts and
experienced echocardiographers with the sharing of skills
and ideas – the CMR approach alone previously adopted
by our group missed septal convexity. The development of
academic silos between imaging modalities should be
resisted: breaking them down increases insights for patient
care. Reverse septal curvature is well known in overt HCM
patients to be related to a higher incidence of pathological
gene mutation detection (79 % of the HCM patients with
MYBPC3 mutation and absent in those without the
Fig. 4 ROC curves for the SCx. SCx≥ 3.55 mm had optimal sensitivity
and specificity to differentiate the two groups
Fig. 5 Bland-Altman analysis: intra- and interobserver variability of SCx measurements
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mutation in one paper) [15]. More recently, Binder et al.
described an important genotype-phenotype relationship
linking the genetic substrate to the morphologic shape
[18]. The analysis of a large cohort of genotyped and echo-
cardiographically characterized patients reveals that nearly
80 % of HCM patients with reverse septal curvature have
a positive genetic test for myofilament HCM, whereas the
same genetic test is positive in fewer than 10 % of patients
clinically diagnosed with HCM, but having a sigmoidal
septal morphology [18]. However, it has not been previ-
ously described that reverse septal curvature could be a
subclinical characteristic of HCM. This is addressed by
our present study.
Septal convexity is a straightforward measure that can
be taken from a standard four chamber cine image, and
we provide a cut-point for analysis. Short axis views did not
show the curvature – we think that part of the curvature is
the centre point of the blood pool cavity not lying on a
straight line – the familiar “banana shaped” cavity from
overt HCM. Thus a “stack of discs” that are the short axis
cines are not aligned, but any one SA view can be normal;
only a view (4 chamber) showing the cavity from base to
apex fully shows the distortion. Although ultimately this
measure is likely to be assessed in combination with other
known subclinical features of HCM (elongation of the
AMVL, myocardial crypts, etc..) this technique could
potentially also be applied to echocardiographic images
More sophisticated methods could be used to assess
septal curvature [19], and the technique may well work
on echocardiographic images.
Limitations
This is a single centre study. Preclinical HCM requires the
presence of a known pathogenic mutation – early detec-
tion is really most needed where such mutations are not
present. Follow-up is necessary to confirm that this abnor-
mality precedes or predicts the subsequent development
of significant LVH. Larger prospective cohorts of mutation
carriers and individuals with a pretest probability of 50 %
are needed, especially to determine subclinical phenotypic
differences between specific gene mutations.
We did not observe significant differences between the
two groups when assessment of septal convexity was
performed in short axis. This is probably due to a different
approach with different benchmarks, different scale of
distance, and a different direction of measurement. So,
we recommend using apical 4 chamber view approach
to differentiate subjects. Intra- and inter-observer vari-
abilities were good in spite of the absolute values (only
a few millimeters) of our measurements. Several factors
such as ethnicity, age, gender, and hypertension might
impact septal convexity. In this present case control study,
our population was highly selected and predominantly
comprised white females aged <60 years. No subject
had hypertension. We acknowledge that in clinical prac-
tice, septal convexity into LV should be used and inter-
preted with caution, and used only for Caucasian
relatives of HCM patients, <60 years old, and without
hypertension. Echocardiographically, septal curvature has
been assessed in overt HCM by a method using the radius
of curves matching the endocardial border [19]. Further
research should address whether repeating these ana-
lyses by CMR and their eventual semi-automation
provide superior insights.
Conclusions
Septal convexity (into the LV) is an additional previously
unrecognized feature of subclinical HCM. It should be
assessed in combination with other known subclinical
HCM features, occurring in the absence of LV hypertrophy.
Further studies with follow-up are necessary to confirm
that septal convexity really precedes LVH in HCM mu-
tation careers.
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TNNI3: Troponin I; TNNT2: Troponin T.
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